drugset / Trial / NCT00852371

Intermittent Preventive Treatment of Malaria in Schoolchildren

NCT00852371

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This will be a randomized, single-blinded, placebo-controlled trial to evaluate the efficacy, safety and tolerability of antimalarial regimens in healthy schoolchildren. The primary objective of the study is to compare the efficacy of different combination antimalarial regimens, including amodiaquine + sulfadoxine-pyrimethamine (AQ+SP), dihydroartemisinin-piperaquine (DP), and placebo, to SP for intermittent preventive treatment (IPT) in schoolchildren, as measured by risk of parasitaemia (unadjusted by genotyping) after 42 days of follow-up. This will assess both the efficacy for treatment of asymptomatic infections and the efficacy for prevention of new infections.

Timeline

Start
2008-02
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator ARTENIMOL Small molecule 2.1 mg/kg
Comparator amodiaquine Other / unclassified 10 mg/kg Oral
Comparator piperaquine Small molecule 17.1 mg/kg
Comparator pyrimethamine Small molecule 1.25 mg/kg Oral
Comparator sulfadoxine Small molecule 25 mg/kg Oral

Indications